Over the past 3 months, there was an explosion of articles describing the clinical, imaging, and pathological features of familial amyotrophic lateral sclerosis and frontotemporal dementia associated with the C9ORF72 hexanucleotide repeat expansion. A proposal for amyotrophic lateral sclerosis staging and an overview of changing utilization of noninvasive ventilation in the United Kingdom are also reviewed. There was also an interesting series of articles on generalized myasthenia gravis that is seronegative for acetylcholine receptor and muscle-specific kinase antibodies but harbors antibodies against the low-density lipoprotein receptor-related protein 4, which binds agrin on the postsynaptic cleft and seems to play a pathogenic role in myasthenia gravis. The clinically important disorder, small fiber neuropathy (SFN), is also reviewed including an important discovery of sodium channel Na v 1.7 mutations in patients with previously idiopathic SFN and a treatment approach for SFN using a Na v 1.7 channel blocker. Another important article expands the phenotypes of anoctamin 5 autosomal recessive limb-girdle muscular dystrophy. Presentations were variable with adult-onset sometimes asymmetric weakness with proximal and sometimes calf involvement and high creatine kinase. Females were less severely affected and often had exercise induced myalgia without weakness.
The recent description of a large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 on chromosome 9p was an exciting development in amyotrophic lateral sclerosis (ALS) research, especially because this mutation is associated with 40% of cases of familial amyotrophic lateral sclerosis (fALS). performed extensive neuropathologic investigations on 10 Dutch patients with FTD with or without ALS with the C9ORF72 mutation. Their population had predominant temporal atrophy on neuroimaging. Histopathologically, they also found TDP-43 pathology in all brains and p62-positive inclusions in the cerebellar granular layer in 9 of 11 brains. They performed in situ hybridization for RNA containing GGGGCC repeats and did not find a consistent pattern in brains with the C9ORF72 mutation and other forms of FTD. It is still not certain as to how the C9ORF72 mutation causes motor neuron degeneration, but it has been hypothesized that the pathologic expansion causes RNA toxicity as has been seen in other forms of repeat diseases including myotonic dystrophy. The C9ORF72 mutation shares TDP-43 pathology with other forms of ALS, and additional insight into pathogenesis may follow development of a nonhuman primate model of ALS using adeno-associated virus vector overexpression of TDP-43 in spinal cords. Uchida Small fiber neuropathy (SFN) is relatively common, often of undetermined etiology, and frequently frustrating to patients and their physicians. The main feature is neuropathic pain, and some patients have dysautonomia. The sodium channel subtype Na v 1.7 is expressed in dorsal root ganglia, sympathetic, and other small diameter peripheral axons. Mutations in the SCN9A gene result in gain of function of voltage-gated sodium channel Na v 1.7 with neuronal hyperexcitability as have been reported in rare autosomal dominant early-onset pain syndromes, namely, paroxysmal extreme pain syndrome and inherited erythromelalgia (IEM). More recently, Na v 1.7 channel mutations have been reported in another rare, early-onset, inherited syndrome of painful SFN and small hands and feet (acromesomelia) and in an impressive proportion of previously idiopathic small fiber neuropathy.
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Faber et al 20 reported Na v 1.7 mutations in a substantial proportion (28.6%, 8 of 28) of Dutch patients with idiopathic small fiber neuropathy. The patients met strict criteria for SFN including skin biopsy with reduced intraepidermal nerve fiber density and abnormal quantitative sensory testing for thermal thresholds without an underlying etiology for SFN. All 8 patients complained of pain that involved the distal extremities (with the feet being more involved than hands) in most patients, but sometimes, it began more diffusely or rarely in the face. Pain was aggravated by warmth in 3 patients. Mean age of onset of symptoms was 32.4 years.
Other mutations in the SCN9A gene result in loss of function or deficiency of Na v 1.7 and are associated with congenital indifference to pain. This autosomal recessive syndrome leads to a lack of pain sensation associated with noxious stimuli. 24 Hence, it is reasonable to assume that nonspecific sodium channel or Na v 1.7-selective blockers may offer a therapeutic approach in slowing axonal degeneration and alleviating the pain in patients with Na v 1.7 mutations. Goldberg et al 25 tested this theory by treating SCN9A mutation-proven IEM patients, who carry the mutant Na v 1.7, with Na v 1.7-selective blockers. A novel sodium channel blocker (Xen402) was tested in a randomized, double-blind, 2-period, crossover study. Each treatment period was 2 days, separated by a 2-day washout period with the primary aim of demonstrating that Xen402 alleviates pain associated with IEM. Four patients were enrolled; in 3, pain was triggered by exercise or heat during each treatment arm. The fourth patient required no induction because the patient was in constant severe pain. Two patients had dizziness or somnolence. Pain was reduced by 42% compared with placebo, and the ability to induce pain was significantly attenuated in the 2 hours after induction in 3 patients. The fourth patient reported improvement in constant pain. However, there were several study limitations including short study duration, small sample size, and lack of specific endpoints. The study also focused on inducible pain, whereas persistent pain is generally the main clinical challenge. Although this treatment approach seems to offer considerable promise in the treatment of neuropathic pain, especially in patients with SFN with Na v 1.7 mutations, the results of this study should be interrupted with caution.
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Limb-girdle muscular dystrophies (LGMDs) also frustrate clinicians for reasons dissimilar from those related to SFN. Confirming a diagnosis is complicated because clinical clues overlap and selecting appropriate genetic testing is often confusing and usually expensive. It is always good to learn about common forms that we can first look into. Therefore, we welcomed the relatively recent identification of recessive Anoctamin 5 (ANO5) mutations as a common cause of autosomal recessive LGMD. [26] [27] [28] LGMD, calf distal myopathy, or CK levels above 2000 IU/L and were tested for ANO5 mutations. Eleven different recessive ANO5 mutations were identified in 25 patients (16 males and 9 females). The most common mutation was c.2272C>T (p.R758C). However, c.191dupA reported in the previous study was the second most common. The phenotype of the 25 patients varied from exercise-related myalgias, high CK level, and calf hypertrophy to severe proximal LGMD. The mean age of symptom onset was 37 years. Of the 16 male patients, 13 had proximal weakness with lower limbs being more affected than upper with an exception of one patient with weakness and atrophy of biceps brachii at onset. Three of 16 male patients had pure calf weakness and atrophy. However, the phenotype was different and milder in female patients because none of them had clinically detectable muscle weakness. They had high CK levels, severe fatty changes on MRI, and myopathic changes in the muscle biopsy. The presenting symptoms were high CK levels for many years, myalgia, exercise intolerance, and calf hypertrophy.
In agreement with the previous study, the disease was slowly progressive with no significant cardiac or pulmonary involvement and asymmetry of the muscle involvement was present. Of note, several patients had an elevated alanine aminotransferase and 2 of them underwent a liver biopsy for suspected liver disease. Interestingly, 2 patients were initially diagnosed with myositis based on hyperCKemia and occasional lymphocytic infiltrations in muscle biopsy. In conclusion, recessive ANO5 mutations cause adult-onset slowly progressive muscular dystrophy with variable phenotypes with high CK levels and no significant cardiac or respiratory involvement. The phenotype varies between sexes with females being less severely affected and more likely to present with exercise intolerance than weakness. Recessive ANO5 mutations are a common cause of muscular dystrophy and may be the most common cause of LGMD in Finland. 30 
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